The Default Library
Library / Drugs

Ketamine: A Battlefield Anesthetic That Became a Psychiatric Breakthrough

In 2000, a small study found that a single low-dose IV infusion of a decades-old battlefield anesthetic produced rapid, significant relief from depression — in some patients, within hours, for a condition where standard antidepressants typically take weeks to work at all, if they work. That finding launched what's now one of the more genuine, FDA-recognized psychiatric breakthroughs of the last quarter-century, running in parallel with the drug's much older reputation as a club-scene dissociative.

5 min readRead

From battlefield to nightclub to psychiatrist's office

Ketamine was synthesized in 1962 by chemist Calvin Stevens as a safer replacement for PCP, and the FDA approved it as an anesthetic in 1970. Its specific medical value was quickly proven under the worst possible test conditions: it became a widely used field anesthetic during the Vietnam War, valued specifically because, unlike many other anesthetics, it doesn't significantly suppress breathing or blood pressure — a genuinely important safety property in a battlefield setting without full monitoring equipment. It remains in common medical and veterinary use as an anesthetic today. Recreational use under the name "Special K" emerged in club and party scenes starting in the 1980s, centered on ketamine's distinctive dissociative effects — at higher doses, a state often called the "k-hole," an intense, often disorienting separation from ordinary body and reality perception.

The depression breakthrough

The landmark 2000 study in Biological Psychiatry (Berman and colleagues at Yale) was a tiny placebo-controlled trial — seven patients completed it — in people with major depression, and it showed relief within hours. In 2006 a larger trial at the U.S. National Institute of Mental Health (Zarate and colleagues, 18 patients, in Archives of General Psychiatry) confirmed the rapid effect specifically in treatment-resistant depression — people for whom standard antidepressants (which work on a fundamentally different, slower-acting mechanism) had already failed. This was a genuinely novel finding: nothing in psychiatry's existing toolkit worked this fast. In 2019, the FDA approved esketamine (brand name Spravato), a nasal spray formulation derived from ketamine, specifically for treatment-resistant depression — the first ketamine-derived medication to receive that approval. Since then, ketamine clinics — offering off-label IV or intramuscular ketamine treatment for depression, generally outside the specific Spravato protocol — have grown from a handful to an estimated hundreds or thousands of locations across the U.S.

What it actually does, and the real dangers

Ketamine is a dissociative anesthetic — at sub-anesthetic (lower) doses, it produces a sense of detachment from the body and surroundings alongside its antidepressant and mild analgesic effects; at higher doses, it produces genuine anesthesia (loss of consciousness and pain sensation) and, at unsupervised recreational doses, the k-hole.

Impaired coordination and judgment during dissociation is a real, immediate safety risk. Someone dissociated from their body and surroundings is at real risk of injury — falls, accidents, an inability to respond to danger — which is exactly why clinical ketamine treatment happens in a monitored medical setting, and why unsupervised recreational use in an uncontrolled environment carries meaningfully more risk than the clinical version of the same drug.

Chronic heavy recreational use causes real, sometimes permanent bladder damage. This is a well-documented, serious condition called ketamine-induced cystitis (sometimes described as "ketamine bladder") — chronic heavy use can cause ulceration and inflammation of the bladder lining, leading to pain, urinary urgency, incontinence, and in severe, longstanding cases, permanent bladder shrinkage and damage requiring surgical intervention. This is a genuinely underrecognized risk specific to ketamine among the drugs in this category.

"K-pains." Chronic heavy users also report severe abdominal pain, sometimes called K-pains or K-cramps, another distinctive marker of heavy long-term use.

Dangerous combined with other depressants. Combining ketamine with alcohol or other sedating drugs compounds respiratory and cardiac risk, similar to the combination dangers described for benzodiazepines elsewhere in this category.

Not classically physically addictive like opioids, but real psychological dependence patterns exist, particularly with frequent recreational use, and tolerance can build with regular use.

Ketamine is a rare case in this category where the same molecule, at a lower dose in a monitored clinical setting, represents one of psychiatry's most promising recent tools — and, at higher doses in an unsupervised recreational setting, carries real risks including a specific, serious, and often overlooked risk to bladder health that has nothing to do with its psychiatric promise at all.

The genuine promise, stated honestly

Ketamine and esketamine represent a real, FDA-recognized advance specifically for treatment-resistant depression — a population that, by definition, hasn't responded to other available treatments, and for whom a rapid-acting option is a meaningful clinical addition, not a marginal one. Active research is exploring ketamine's potential for PTSD, OCD, and certain substance use disorders as well, though these applications remain earlier-stage and less established than the depression evidence.

Try this

If ketamine touches your life — clinically or recreationally — know the specific bladder-damage risk described above; it's one of the least publicly known serious risks in this entire category, disproportionate to how much attention it typically gets compared to more famous psychedelic risks.

The takeaway

Ketamine has lived two very different lives since 1962: a genuinely valuable battlefield and medical anesthetic, and — since a landmark 2000 study — one of psychiatry's most promising recent tools for treatment-resistant depression, formalized in the FDA-approved esketamine nasal spray in 2019. It also has a long-running recreational history as a club dissociative, "Special K," where unsupervised use at higher doses carries real risk of injury during dissociation and, with chronic heavy use, a serious and often underrecognized risk of permanent bladder damage. The clinical and recreational versions of this drug carry meaningfully different risk profiles, driven substantially by dose, setting, and supervision.

Try this: if ketamine is part of your life in any form, learn the specific signs of ketamine-induced bladder damage — it's one of the most serious, least publicized risks in this entire category.

Sources & Further Reading

Sources
- Ketamine's 1962 synthesis, 1970 FDA anesthetic approval, and Vietnam War battlefield use reflect standard pharmacological and medical history.
- Berman RM, et al., "Antidepressant effects of ketamine in depressed patients," Biological Psychiatry 47 (2000): 351–354; Zarate CA Jr, et al., "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression," Archives of General Psychiatry 63 (2006): 856–864. The 2019 FDA esketamine (Spravato) approval reflects published regulatory documentation.
- Ketamine-induced cystitis and "K-pains" reflect published clinical and urological case literature.
- Current ketamine clinic prevalence reflects current 2026 industry and clinical reporting.

Go deeper
- 🌐 Search "ketamine cystitis bladder damage symptoms" for detailed clinical information on this underrecognized risk
- 🌐 NAMI.org — information on ketamine and esketamine as depression treatments
- 🌐 Related pieces in this library: The Real Harm Ladder, this category, and Psilocybin, for another substance with a parallel rapid clinical-legitimacy trajectory

Drugs, HonestlyStep 14 of 18
Next on this path →Ayahuasca: The Brew That Turned Chemistry Into Ceremony
← Previous in section
Nicotine & Tobacco: The Deadliest Drug in This Entire Category

Related in Drugs

•

The Real Harm Ladder

The most dangerous drug most people use is legal, sold at every gas station, and rarely thought of as a "drug" at all. Before the rest of this category goes substance by substance, here's what the actual published evidence says about which drugs cause the most harm — not which ones are illegal.

4 min•

LSD: The Accident That Became a Movement, a Menace, and (Maybe) a Medicine

A Swiss chemist synthesized it in 1938 while researching a completely different problem, set it aside as uninteresting, and only rediscovered its effects five years later by accident — absorbing a trace through his fingertips and experiencing what he described as a stream of fantastic, kaleidoscopic imagery. That accident produced one of the most powerful psychoactive substances ever discovered, active in doses measured in millionths of a gram, and one of the most legally punished. Here's the honest version: what LSD actually does, why it went from psychiatric tool to street drug to psychiatric tool again, and what current research does and doesn't support.

6 min•

Psilocybin: The Mushroom That's Closest to Becoming Medicine

Of every substance in this category, psilocybin mushrooms may be the single closest to a mainstream medical future — with a new-drug application under rolling FDA review (as of autumn 2026), already legal for supervised use in two U.S. states with a third about to follow, and scoring the lowest of any drug in the best-known harm comparison. They're also, in the wrong setting or for the wrong person, capable of triggering a genuinely severe psychological crisis. Both of those things are true at once, and this piece covers both honestly.

5 min